兽医肿瘤市场规模、份额和成长分析（按治疗类型、动物类型、癌症类型、最终用户和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，兽医肿瘤市场规模将达到 2907.9 亿美元，到 2025 年将成长至 3,259.7 亿美元，到 2033 年将成长至 8,128.8 亿美元，在预测期（2026-2033 年）内复合年增长率为 12.1%。

由于宠物癌症发生率的上升以及对兽医肿瘤治疗需求的增长，兽医肿瘤市场正经历显着增长。在兽医肿瘤治疗水准不断提高的推动下，宠物饲主加大了对宠物医疗保健的投入。已开发国家的兽医医疗费用持续上涨，宠物肿瘤疾病的普遍性凸显了改善肿瘤治疗的紧迫性。此外，评估肿瘤治疗的兽医临床试验数量的增加也推动了市场扩张，而诸如美国兽医协会（AVMA）动物健康研究资料库等资源则为研究活动提供了支持。宠物拟人化的趋势加深了饲主与宠物之间的情感纽带，导致宠物饲养量和医疗保健支出增加，最终推动了兽医肿瘤市场的发展。

兽医肿瘤市场驱动因素

伴侣动物（尤其是犬猫）癌症发生率的不断上升是推动兽医肿瘤市场发展的主要因素。随着宠物寿命的延长，它们和人类一样，更容易患上各种疾病，包括癌症。这一趋势促使人们对先进且有效的肿瘤治疗方法的需求日益增长。因此，宠物饲主越来越倾向于寻求专业的兽医护理，这进一步推动了肿瘤领域服务和产品的需求。人们对宠物健康的日益关注以及他们为此投入的意愿，都在支持兽医肿瘤市场的扩张和发展。

兽医肿瘤市场限制因素

兽医肿瘤市场面临的主要挑战之一是癌症治疗的高昂费用，这对饲主来说可能是一个巨大的障碍。这些治疗通常涉及多种服务，包括诊断测试、手术、药物和持续的后续观察，所有这些都可能造成沉重的经济负担。因此，这些必要服务的高昂费用限制了兽医肿瘤治疗的可及性和可负担性，最终影响饲主在需要时为他们心爱的宠物所做的选择。这种经济限制是该产业面临的一个突出挑战。

兽医肿瘤市场趋势

与人类肿瘤学的发展趋势类似，兽医肿瘤学市场正经历着向个人化医疗的重大转变。这种新的关注点优先考虑根据每隻动物的癌症特异性基因特征和生物标记物谱量身定制的个人化治疗方案。透过利用基因组学和诊断技术的进步，兽医肿瘤学家能够在提高治疗效果的同时减少副作用，最终改善患者的预后。这种个人化方法不仅能够实现更精准的治疗策略，还能满足饲主对其爱宠日益增长的高品质、个人化照护的期望，从而进一步推动兽医肿瘤学领域的创新和投资。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究

全球兽医肿瘤市场规模（按治疗类型和复合年增长率划分）（2026-2033 年）

• 化疗
  • 口服化疗
  • 注射化疗
• 放射线治疗
  • 体外放射线治疗
  • 体内放射疗法
• 免疫疗法
  • 单株抗体
  • 癌症疫苗
• 外科手术
  • 肿瘤切除
  • 重组手术

全球兽医肿瘤市场规模（依动物类型划分）及复合年增长率（2026-2033 年）

• 伴侣动物
  • 狗
  • 猫
• 家畜
  • 牛
  • 羊
  • 猪

全球兽医肿瘤市场规模（按癌症类型和复合年增长率划分）（2026-2033 年）

• 淋巴瘤
• 肥大细胞瘤
• 黑色素瘤
• 乳腺腺癌和鳞状细胞癌
• 其他的

全球兽医肿瘤市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 兽医诊所
• 动物诊所
• 研究所
• 其他的

全球兽医肿瘤市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Zoetis Inc.（USA）
• Elanco Animal Health（USA）
• Boehringer Ingelheim（Germany）
• Merck Animal Health（USA）
• Virbac（France）
• Ceva Sante Animale（France）
• Vetoquinol（France）
• Dechra Pharmaceuticals（UK）
• IDEXX Laboratories（USA）
• Heska Corporation（USA）
• Aratana Therapeutics（USA）
• Karyopharm Therapeutics（USA）
• Regeneus Ltd.（Australia）
• PetCure Oncology（USA）
• Accuray Incorporated（USA）
• Varian Medical Systems（USA）
• Morphogenesis, Inc.（USA）
• Nippon Zenyaku Kogyo Co., Ltd.（Japan）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）

结论与建议

Veterinary Oncology Market size was valued at USD 290.79 Billion in 2024 and is poised to grow from USD 325.97 Billion in 2025 to USD 812.88 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

Veterinary oncology is experiencing significant market growth driven by an increase in cancer incidence among pets and a heightened demand for veterinary cancer treatments. Pet owners are increasingly investing in animal healthcare, fueled by initiatives aimed at improving veterinary oncology. In developed countries, spending on animal healthcare is on the rise, and the prevalence of neoplastic diseases in pets underlines the urgent need for better oncology treatments. Additionally, an upswing in veterinary clinical trials evaluating oncologic therapies further supports market expansion, with resources like the AVMA Animal Health Research Database aiding research efforts. The pet humanization trend is promoting closer bonds between owners and their pets, leading to increased pet adoption and healthcare spending, ultimately boosting the veterinary oncology market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Veterinary Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Veterinary Oncology Market Segments Analysis

Global Veterinary Oncology Market is segmented by therapy type, animal type, cancer type, end-user and region. Based on therapy type, the market is segmented into chemotherapy, radiation therapy, immunotherapy and surgery. Based on animal type, the market is segmented into companion animals and livestock animals. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer and others. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Veterinary Oncology Market

The increasing occurrence of cancer among companion animals, particularly dogs and cats, significantly propels the veterinary oncology market. As pets enjoy longer lifespans, they become more vulnerable to various health issues, including cancer, similar to humans. This trend creates a growing need for advanced and effective oncology treatments to address these conditions. Consequently, pet owners are more inclined to seek specialized veterinary care, further fueling the demand for services and products within the oncology sector. This heightened awareness around pet health and the willingness to invest in their well-being underscores the expansion and evolution of the veterinary oncology market.

Restraints in the Veterinary Oncology Market

One of the primary challenges facing the veterinary oncology market is the substantial expense associated with cancer treatments, which can present a significant barrier for pet owners. These treatments often encompass a range of services, including diagnostic testing, surgical procedures, medication, and ongoing follow-up care, all of which can accumulate into a considerable financial burden. As a result, the high costs associated with these essential services can restrict the accessibility and affordability of veterinary oncology, ultimately impacting the choices pet owners can make for their beloved animals in times of need. This financial constraint is a prominent issue in the industry.

Market Trends of the Veterinary Oncology Market

The veterinary oncology market is witnessing a significant shift towards personalized medicine, akin to trends in human oncology. This emerging focus prioritizes individualized treatment plans that align with the unique genetic characteristics and biomarker profiles of each animal's cancer. By leveraging advancements in genomics and diagnostics, veterinary oncologists can enhance therapeutic efficacy while reducing adverse effects, ultimately leading to improved patient outcomes. This tailored approach not only fosters a more precise treatment strategy but also aligns with pet owners' increasing expectations for high-quality, customized care for their beloved animals, driving further innovation and investment in the veterinary oncology sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Veterinary Oncology Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
  • Oral Chemotherapy
  • Injectable Chemotherapy
• Radiation Therapy
  • External Beam Radiation Therapy
  • Internal Radiation Therapy
• Immunotherapy
  • Monoclonal Antibodies
  • Cancer Vaccines
• Surgery
  • Tumor Removal
  • Reconstructive Surgery

Global Veterinary Oncology Market Size by Animal Type & CAGR (2026-2033)

• Market Overview
• Companion Animals
  • Dogs
  • Cats
• Livestock Animals
  • Cattle
  • Sheep
  • Pigs

Global Veterinary Oncology Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary And Squamous Cell Cancer
• Others

Global Veterinary Oncology Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Hospitals
• Veterinary Clinics
• Research Institutes
• Others

Global Veterinary Oncology Market Size & CAGR (2026-2033)

• North America (Therapy Type, Animal Type, Cancer Type, End-User)
  • US
  • Canada
• Europe (Therapy Type, Animal Type, Cancer Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Animal Type, Cancer Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Animal Type, Cancer Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Animal Type, Cancer Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heska Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aratana Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accuray Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Morphogenesis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nippon Zenyaku Kogyo Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations